UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

The New England journal of medicine, 2019-03, Vol.380 (10), p.981-983

2019

Volltextzugriff (PDF)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

The Lancet (British edition), 2019-08, Vol.394 (10198), p.576-586

2019

Volltextzugriff (PDF)

Trial of Spesolimab for Generalized Pustular Psoriasis

The New England journal of medicine, 2021-12, Vol.385 (26), p.2431-2440

2021

Volltextzugriff (PDF)

Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Therapeutic Advances in Musculoskeletal Disease, 2017-11, Vol.9 (11), p.277-294

2017

Volltextzugriff (PDF)

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

The New England journal of medicine, 2014-07, Vol.371 (4), p.326-338

2014

Volltextzugriff (PDF)

Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan

Journal of dermatological science, 2011-07, Vol.63 (1), p.40-46

2011

Volltextzugriff (PDF)

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.400-409

2015

Volltextzugriff (PDF)

Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series

Experimental dermatology, 2023-07, Vol.32 (7), p.1048-1050

2023

Volltextzugriff (PDF)

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study

Journal of dermatology, 2023-02, Vol.50 (2), p.183-194

2023

Volltextzugriff (PDF)

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

The Lancet (British edition), 2023-10, Vol.402 (10412), p.1541-1551

2023

Volltextzugriff (PDF)

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Journal of the American Academy of Dermatology, 2017-01, Vol.76 (1), p.60-69.e9

2017

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Elderly‐onset generalized pustular psoriasis: a case series

Clinical and experimental dermatology, 2022-08, Vol.47 (8), p.1567-1570

2022

Volltextzugriff (PDF)

Burden of atopic dermatitis in Asia

Journal of dermatology, 2019-10, Vol.46 (10), p.825-834

2019

Volltextzugriff (PDF)

Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature

Lupus, 2022-06, Vol.31 (7), p.891-894

2022

Volltextzugriff (PDF)

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work

Journal of dermatology, 2018-11, Vol.45 (11), p.1353-1356

2018

Volltextzugriff (PDF)

Response to “a case of acquired idiopathic generalized anhidrosis following severe acute respiratory syndrome coronavirus 2 vaccination”

Journal of dermatology, 2024-01, Vol.51 (1), p.e22-e23

2024

Volltextzugriff (PDF)

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

International journal of molecular sciences, 2022-05, Vol.23 (10), p.5518

2022

Volltextzugriff (PDF)

Acquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?

Experimental dermatology, 2024-03, Vol.33 (3), p.e15056-n/a

2024

Volltextzugriff (PDF)

Deficiency of interleukin‐36 receptor antagonist (DITRA): An analysis of 58 Chinese patients in a tertiary hospital in Taiwan

Experimental dermatology, 2023-08, Vol.32 (8), p.1272-1278

2023

Volltextzugriff (PDF)

Lack of IL36RN sequence variation in three Chinese patients with subcorneal pustular dermatoses

Journal of dermatology, 2024-11, Vol.51 (11), p.e412-e413

2024

Volltextzugriff (PDF)

Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan

Journal of dermatology, 2020-09, Vol.47 (9), p.1046-1049

2020

Volltextzugriff (PDF)

Acquired idiopathic generalized anhidrosis diagnosed following mRNA COVID‐19 vaccination—A case series

Australasian journal of dermatology, 2023-02, Vol.64 (1), p.e76-e79

2023

Volltextzugriff (PDF)

Report of a case with CARD14‐associated papulosquamous eruptions and multiple skin cancers

Photodermatology, photoimmunology & photomedicine, 2024-05, Vol.40 (3), p.e12969-n/a

2024

Volltextzugriff (PDF)

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

Experimental dermatology, 2023-12, Vol.32 (12), p.2138-2148

2023

Volltextzugriff (PDF)

1 – 25 von 430

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(385)
Mit Volltextzugriff
(297)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Trial of Spesolimab for Generalized Pustular Psoriasis

Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Elderly‐onset generalized pustular psoriasis: a case series

Burden of atopic dermatitis in Asia

Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work

Response to “a case of acquired idiopathic generalized anhidrosis following severe acute respiratory syndrome coronavirus 2 vaccination”

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

Acquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?

Deficiency of interleukin‐36 receptor antagonist (DITRA): An analysis of 58 Chinese patients in a tertiary hospital in Taiwan

Lack of IL36RN sequence variation in three Chinese patients with subcorneal pustular dermatoses

Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan

Acquired idiopathic generalized anhidrosis diagnosed following mRNA COVID‐19 vaccination—A case series

Report of a case with CARD14‐associated papulosquamous eruptions and multiple skin cancers

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

Suchergebnisse filtern